276 related articles for article (PubMed ID: 31935470)
1. In vivo preclinical evaluation of the new
Trencsényi G; Kis A; Szabó JP; Ráti Á; Csige K; Fenyvesi É; Szente L; Malanga M; Méhes G; Emri M; Kertész I; Vecsernyés M; Fenyvesi F; Hajdu I
Int J Pharm; 2020 Feb; 576():118954. PubMed ID: 31935470
[TBL] [Abstract][Full Text] [Related]
2. In vivo investigation of Gallium-68 and Bismuth-205/206 labeled beta cyclodextrin for targeted alpha therapy of prostaglandin E2 receptor-expressing tumors in mice.
Csige K; Szabó JP; Kálmán-Szabó I; Dénes NS; Szikra D; Képes Z; Opposits G; Méhes G; Kertész I; Fenyvesi F; Trencsényi G; Hajdu I
Int J Pharm; 2022 Sep; 625():122132. PubMed ID: 36028082
[TBL] [Abstract][Full Text] [Related]
3. In vivo assessment of tumor targeting potential of
Szabó JP; Csige K; Kálmán-Szabó I; Arató V; Opposits G; Jószai I; Kertész I; Képes Z; Méhes G; Fenyvesi F; Hajdu I; Trencsényi G
Int J Pharm; 2023 Jan; 630():122462. PubMed ID: 36462739
[TBL] [Abstract][Full Text] [Related]
4. Overview of Prostaglandin E2 (PGE2)-Targeting Radiolabelled Imaging Probes from Preclinical Perspective: Lessons Learned and Road Ahead.
Képes Z; Dénes N; Kertész I; Hajdu I; Trencsényi G
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108106
[TBL] [Abstract][Full Text] [Related]
5. Radiochemical synthesis and preclinical evaluation of
Hajdu I; Angyal J; Szikra D; Kertész I; Malanga M; Fenyvesi É; Szente L; Vecsernyés M; Bácskay I; Váradi J; Fehér P; Ujhelyi Z; Vasvári G; Rusznyák Á; Trencsényi G; Fenyvesi F
Eur J Pharm Sci; 2019 Feb; 128():202-208. PubMed ID: 30521943
[TBL] [Abstract][Full Text] [Related]
6. Comparative preclinical evaluation of
Trencsényi G; Dénes N; Nagy G; Kis A; Vida A; Farkas F; Szabó JP; Kovács T; Berényi E; Garai I; Bai P; Hunyadi J; Kertész I
J Pharm Biomed Anal; 2017 May; 139():54-64. PubMed ID: 28273651
[TBL] [Abstract][Full Text] [Related]
7. In vivo imaging of folate receptor positive tumor xenografts using novel 68Ga-NODAGA-folate conjugates.
Fani M; Tamma ML; Nicolas GP; Lasri E; Medina C; Raynal I; Port M; Weber WA; Maecke HR
Mol Pharm; 2012 May; 9(5):1136-45. PubMed ID: 22497506
[TBL] [Abstract][Full Text] [Related]
8. First-In-Human Study Demonstrating Tumor-Angiogenesis by PET/CT Imaging with (68)Ga-NODAGA-THERANOST, a High-Affinity Peptidomimetic for αvβ3 Integrin Receptor Targeting.
Baum RP; Kulkarni HR; Müller D; Satz S; Danthi N; Kim YS; Brechbiel MW
Cancer Biother Radiopharm; 2015 May; 30(4):152-9. PubMed ID: 25945808
[TBL] [Abstract][Full Text] [Related]
9. Comparison of two new angiogenesis PET tracers 68Ga-NODAGA-E[c(RGDyK)]2 and (64)Cu-NODAGA-E[c(RGDyK)]2; in vivo imaging studies in human xenograft tumors.
Oxboel J; Brandt-Larsen M; Schjoeth-Eskesen C; Myschetzky R; El-Ali HH; Madsen J; Kjaer A
Nucl Med Biol; 2014 Mar; 41(3):259-67. PubMed ID: 24417983
[TBL] [Abstract][Full Text] [Related]
10. 68Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers.
Persson M; Madsen J; Østergaard S; Ploug M; Kjaer A
Nucl Med Biol; 2012 May; 39(4):560-9. PubMed ID: 22172391
[TBL] [Abstract][Full Text] [Related]
11. (64)Cu- and (68)Ga-Based PET Imaging of Folate Receptor-Positive Tumors: Development and Evaluation of an Albumin-Binding NODAGA-Folate.
Farkas R; Siwowska K; Ametamey SM; Schibli R; van der Meulen NP; Müller C
Mol Pharm; 2016 Jun; 13(6):1979-87. PubMed ID: 27145400
[TBL] [Abstract][Full Text] [Related]
12. Evaluating Ga-68 Peptide Conjugates for Targeting VPAC Receptors: Stability and Pharmacokinetics.
Kumar P; Tripathi SK; Chen CP; Wickstrom E; Thakur ML
Mol Imaging Biol; 2019 Feb; 21(1):130-139. PubMed ID: 29802552
[TBL] [Abstract][Full Text] [Related]
13. Radiolabeling and Preliminary Evaluation of Ga-68 Labeled NODAGA-Ubiquicidin Fragments for Prospective Infection Imaging.
Bhatt J; Mukherjee A; Korde A; Kumar M; Sarma HD; Dash A
Mol Imaging Biol; 2017 Feb; 19(1):59-67. PubMed ID: 27406090
[TBL] [Abstract][Full Text] [Related]
14. PET Probes for Preclinical Imaging of GRPR-Positive Prostate Cancer: Comparative Preclinical Study of [
Kálmán-Szabó I; Szabó JP; Arató V; Dénes N; Opposits G; Jószai I; Kertész I; Képes Z; Fekete A; Szikra D; Hajdu I; Trencsényi G
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077458
[TBL] [Abstract][Full Text] [Related]
15. Molecular Design of HER3-Targeting Affibody Molecules: Influence of Chelator and Presence of HEHEHE-Tag on Biodistribution of
Dahlsson Leitao C; Rinne SS; Mitran B; Vorobyeva A; Andersson KG; Tolmachev V; Ståhl S; Löfblom J; Orlova A
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30832342
[TBL] [Abstract][Full Text] [Related]
16. Development and Validation of an Analytical HPLC Method to Assess Chemical and Radiochemical Purity of [
Migliari S; Sammartano A; Boss M; Gotthardt M; Scarlattei M; Baldari G; Silva C; Bonadonna RC; Ruffini L
Molecules; 2022 Jan; 27(2):. PubMed ID: 35056858
[No Abstract] [Full Text] [Related]
17. Increase in negative charge of
Rinne SS; Dahlsson Leitao C; Gentry J; Mitran B; Abouzayed A; Tolmachev V; Ståhl S; Löfblom J; Orlova A
Sci Rep; 2019 Nov; 9(1):17710. PubMed ID: 31776413
[TBL] [Abstract][Full Text] [Related]
18. Toward realization of 'mix-and-use' approach in ⁶⁸Ga radiopharmacy: preparation, evaluation and preliminary clinical utilization of ⁶⁸Ga-labeled NODAGA-coupled RGD peptide derivative.
Chakraborty S; Chakravarty R; Vatsa R; Bhusari P; Sarma HD; Shukla J; Mittal BR; Dash A
Nucl Med Biol; 2016 Jan; 43(1):116-123. PubMed ID: 26527030
[TBL] [Abstract][Full Text] [Related]
19. Design, Synthesis, and Biological Evaluation of
Liu F; Liu T; Xu X; Guo X; Li N; Xiong C; Li C; Zhu H; Yang Z
Mol Pharm; 2018 Feb; 15(2):619-628. PubMed ID: 29278911
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Ga-68-Labeled Fusarinine C-Based Multivalent RGD Conjugates and [(68)Ga]NODAGA-RGD-In Vivo Imaging Studies in Human Xenograft Tumors.
Zhai C; Franssen GM; Petrik M; Laverman P; Summer D; Rangger C; Haubner R; Haas H; Decristoforo C
Mol Imaging Biol; 2016 Oct; 18(5):758-67. PubMed ID: 26905697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
